Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149011666> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2149011666 abstract "The medical community and patients have long awaited new oral anticoagulants, a substitute for warfarin. Finally, 2 drugs have received limited approval and many more are in various developmental stage. Recently, as a result of the RE-LY study, a phase 3 clinical trial, the FDA approved an oral anticoagulant Dabigatran (Pradaxa), a direct thrombin inhibitor, for prevention of stroke in patients with non-valvular atrial fibrillation. A major advantage is that there is no need for frequent monitoring of coagulation or dose adjustment. Results of the RE-LY study (NEJM) showed that dabigatran 150 mg twice a day has decreased incidence of systemic embolization and stroke but similar rates of major hemorrhage when compared to warfarin. This drug can be used in both outpatient and inpatient settings and has already been approved in 75 countries including many European countries. It is being investigated for many clinical conditions, including prevention and treatment of DVT and pulmonary embolism. The European Medicines Agency approved dabigatran in 2008 for the prevention of thrombo-embolic disease and expanded the indication in 2011. Additional oral Xa inhibitors; apixaban, edoxaban, betrixaban are in different stages of development and likely to get approval for different indications in the near future. Although the market for oral anticoagulants is billions of dollars, safety, clinical, and economic issues will influence the acceptance and use of these drugs. The costs of these drugs is likely to be higher than warfarin, however, elimination of frequent coagulation tests will help reduce overall costs. Important limitations for these new classes of drugs, is the absence of simple, easily available, cost effective reversal agents. This article reviews the clinical trials, pharmacokinetics, side effects and potential clinical applications of these new oral thrombin inhibitors." @default.
- W2149011666 created "2016-06-24" @default.
- W2149011666 creator A5025910656 @default.
- W2149011666 creator A5041926911 @default.
- W2149011666 creator A5045373004 @default.
- W2149011666 date "2011-01-01" @default.
- W2149011666 modified "2023-10-16" @default.
- W2149011666 title "New Anticoagulants for Thrombo-embolic Disease: Clinical Implications" @default.
- W2149011666 cites W1968825981 @default.
- W2149011666 cites W1978892904 @default.
- W2149011666 cites W1979608570 @default.
- W2149011666 cites W1985407614 @default.
- W2149011666 cites W1986637035 @default.
- W2149011666 cites W1997591997 @default.
- W2149011666 cites W1999999021 @default.
- W2149011666 cites W2003726612 @default.
- W2149011666 cites W2029327304 @default.
- W2149011666 cites W2038118250 @default.
- W2149011666 cites W2043674997 @default.
- W2149011666 cites W2067315990 @default.
- W2149011666 cites W2074134943 @default.
- W2149011666 cites W2077084168 @default.
- W2149011666 cites W2095783086 @default.
- W2149011666 cites W2097854437 @default.
- W2149011666 cites W2104488513 @default.
- W2149011666 cites W2112066032 @default.
- W2149011666 cites W2112940339 @default.
- W2149011666 cites W2115787552 @default.
- W2149011666 cites W2132505348 @default.
- W2149011666 cites W2133686162 @default.
- W2149011666 cites W2136489990 @default.
- W2149011666 cites W2151774137 @default.
- W2149011666 cites W2157065952 @default.
- W2149011666 cites W2161844215 @default.
- W2149011666 cites W2164327527 @default.
- W2149011666 cites W2168409771 @default.
- W2149011666 cites W2170483665 @default.
- W2149011666 cites W2102785086 @default.
- W2149011666 doi "https://doi.org/10.4172/2153-0645.1000104" @default.
- W2149011666 hasPublicationYear "2011" @default.
- W2149011666 type Work @default.
- W2149011666 sameAs 2149011666 @default.
- W2149011666 citedByCount "5" @default.
- W2149011666 countsByYear W21490116662012 @default.
- W2149011666 countsByYear W21490116662013 @default.
- W2149011666 countsByYear W21490116662014 @default.
- W2149011666 countsByYear W21490116662016 @default.
- W2149011666 crossrefType "journal-article" @default.
- W2149011666 hasAuthorship W2149011666A5025910656 @default.
- W2149011666 hasAuthorship W2149011666A5041926911 @default.
- W2149011666 hasAuthorship W2149011666A5045373004 @default.
- W2149011666 hasConcept C126322002 @default.
- W2149011666 hasConcept C177713679 @default.
- W2149011666 hasConcept C2779134260 @default.
- W2149011666 hasConcept C71924100 @default.
- W2149011666 hasConceptScore W2149011666C126322002 @default.
- W2149011666 hasConceptScore W2149011666C177713679 @default.
- W2149011666 hasConceptScore W2149011666C2779134260 @default.
- W2149011666 hasConceptScore W2149011666C71924100 @default.
- W2149011666 hasIssue "02" @default.
- W2149011666 hasLocation W21490116661 @default.
- W2149011666 hasOpenAccess W2149011666 @default.
- W2149011666 hasPrimaryLocation W21490116661 @default.
- W2149011666 hasRelatedWork W1839838842 @default.
- W2149011666 hasRelatedWork W1980950179 @default.
- W2149011666 hasRelatedWork W2076985335 @default.
- W2149011666 hasRelatedWork W2082482010 @default.
- W2149011666 hasRelatedWork W2090704721 @default.
- W2149011666 hasRelatedWork W2124125394 @default.
- W2149011666 hasRelatedWork W2315324320 @default.
- W2149011666 hasRelatedWork W2919291229 @default.
- W2149011666 hasRelatedWork W2991533465 @default.
- W2149011666 hasRelatedWork W4252371801 @default.
- W2149011666 hasVolume "02" @default.
- W2149011666 isParatext "false" @default.
- W2149011666 isRetracted "false" @default.
- W2149011666 magId "2149011666" @default.
- W2149011666 workType "article" @default.